Market Monitor - Chemicals performance - Germany

Market Monitor

  • Niemcy
  • Chemia/Farmacja

01 cze 2015

German chemicals/pharmaceuticals businesses have a strong market position, and many are highly specialised. The industry has a well-deserved reputation for innovation and a competitive edge.

Germany

  • Growing production, but decreasing sales prices
  • Payments take 45 days on average
  • Robust solvency and liquidity

 

 

MM_Chemicals_sector_Germany_overview

 

 

The German chemicals industry (including pharmaceuticals) is the largest chemicals industry in Europe and the fourth largest in the world. Of the about 2,000 companies that produce chemical products, more than 90% are small and medium-sized enterprises (SMEs) with less than 500 staff members. SMEs employ one third of the workforce and account for almost one third of total chemicals industry sales. Unlike in other industries, chemicals SMEs are often customers, not suppliers of large chemicals companies.

According to the German chemicals association VCI, production increased 0.6% and turnover rose 0.1% in 2014. In 2015, the VCI expects production to increase 1.5% and turnover to decrease 0.5% (including pharmaceuticals). Excluding pharmaceuticals, production is expected to increase 1.0% and turnover to decrease 1.5%. The decrease in turnover is due to the increased international competition which forces chemicals businesses to immediately pass on lower commodity prices to customers. Chemicals sales prices are expected to decrease by more than 2% in 2015.

 

 

MM_Germany_chemicals_sector_performance

 

In Q1 of 2015 organic basic chemicals accounted for 45% of the production value, followed by petrochemicals (22%), fine and specialty chemicals (20%), polymers (13%), inorganic basic chemicals (10%) and detergents and personal care products (7%). The pharmaceuticals sector accounted for 30% of production value. German chemicals/pharmaceuticals businesses generally have a strong market position, and many are highly specialised. In addition, the industry’s considerable investment in research and development has given it a well-deserved reputation for innovation and a consequent competitive edge.

Generally, German chemicals and pharmaceuticals businesses have robust equity, solvency and liquidity. Profit margins in the chemicals sector are stable overall, although they are influenced by global oil prices. Profit margins in the pharmaceuticals sector are still satisfactory but are shrinking in the domestic market because of the health regulations introduced in 2010. Since then, a number of patents have expired leading to a decline in both turnover and profits from these products. However, pharmaceutical research based manufacturers compensated for this with intensified research and mergers and acquisitions.

 

MM_German_chemicals_strengths_weaknesses

 

The German chemicals and pharmaceuticals sector’s payment behaviour has always been better than average with no notable payment delays, even during the 2008/2009 economic crisis. In our experience payments take, on average, 45 days – even fewer for domestic payments, as most chemical and pharmaceutical products are exported to destinations with longer payment terms than the domestic market. We have seen no change in payment behaviour or increase in notifications of non-payment in the last six months and expect this pattern to continue in the coming months. This should be accompanied by fewer insolvencies in the sector: both chemicals and pharmaceuticals have a lower insolvency rate than other German industries.

 

Our underwriting stance for this sector remains generally relaxed, with normal external monitoring and buyer reviews. However, we pay additional attention to buyers who depend on more critical sectors, such as photovoltaic, which has been affected by insolvencies and restructurings because of reduced public subsidies and strong competition from China.

Powiązane dokumenty

Zwolnienie z odpowiedzialności

Sformułowania zawarte w niniejszym dokumencie mają wyłącznie ogólny charakter informacyjny i firma nie ponosi odpowiedzialności za ich wykorzystanie. Warunki regulujące znajdują się w aktualnej polisie ubezpieczeniowej albo we właściwej umowie dostarczenia produktów lub świadczenia usług. Żadnego z zawartych w tym dokumencie stwierdzeń nie należy interpretować jako powstania prawa, obowiązku, rekomendacji lub odpowiedzialności ze strony spółki Atradius, w tym obowiązku przeprowadzenia analizy due diligence nabywcy lub w Państwa imieniu. Jeśli spółka Atradius przeprowadza analizę due diligence dowolnego nabywcy, robi to wyłącznie do własnych celów związanych z działalnością ubezpieczeniową a nie na rzecz ubezpieczonego lub jakiegokolwiek innego podmiotu. Ponadto spółka Atradius ani jej podmioty powiązane, stowarzyszone lub zależne w żadnym wypadku nie ponosi odpowiedzialności za bezpośrednie, pośrednie, szczególne, przypadkowe lub wynikowe powstałe wskutek wykorzystania stwierdzeń zawartych w niniejszym dokumencie.